HP-518 is under clinical development by Hinova Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HP-518’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hinova Pharmaceuticals overview
Hinova Pharmaceuticals (Hinova Pharma) operates as a drug discovery and development company. The Company focuses on the therapeutic areas where there are unmet medical needs. Hinova Pharmaceuticals serves customers globally. Hinova Pharma is headquartered in Chengdu, Sichuan, China.
For a complete picture of HP-518’s drug-specific PTSR and LoA scores, buy the report here.